Cohava Gelber, PhD, MBA, is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. Dr. Gelber held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation).

She recently launched Caerus Discovery, LLC (CDL) with support from Biowa/ Kyowa Hakko Kirin.  CDL ‘s mission is to discover and develop new antibody-based therapeutics and diagnostics.  Prior to founding CDL, Cohava Gelber served as the Chief Scientific & Technology Officer of ATCC, VP of R&D for MannKind Corp- a public company developing therapeutics for diabetes, cancer and autoimmune diseases and was responsible for non-clinical development and clinical immune safety of drugs from pre IND through phase III clinical trials. She received her PhD from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University.

She published numerous scientific manuscripts and textbook chapters and she is the inventor of 16 granted patents and 57 patent applications.